Tagad jūs pametat Viatris Latvija vietni, lai pārietu uz Viatris partnera vietni vai trešās puses vietni, kas ir pilnībā atbildīga par tās saturu, tostarp par atbilstību noteiktos reģionos piemērojamām vadlīnijām. Saites uz Viatris partneru vietnēm un trešo pušu vietnēm tiek nodrošinātas kā resursi mūsu apmeklētājiem, un uz tām var neattiekties tās pašas normatīvās prasības, kas attiecas uz šo vietni, un uz nesaistītām trešo pušu vietnēm attiecas savi noteikumi un datu aizsardzības paziņojumi un prakse. Turklāt, ja trešās puses vietni regulē citas valsts tiesību akti, normatīvās prasības, datu aizsardzības prasības vai medicīniskā prakse dažādās valstīs var atšķirties, un tajā ietvertā informācija var nebūt piemērota lietošanai jūsu valstī.
Viatris redefines the healthcare landscape through strong leadership
Thanks to their strong expertise, knowledge and strategic vision of our healthcare environment, our executive management team brings unmatached value to Viatris all over the world.
Executive management
Robert J. Coury
Executive Chairman
After leading the transformation of Mylan into one of the world's largest global pharmaceutical companies, Robert J. Coury again led the company to another level by combining forces with Upjohn to form Viatris, a new champion for global health. His strategic vision and leadership guide the company's performance and growth.
Viatris chief executive officer Scott A. Smith is a deeply knowledgeable senior global biotechnology and pharmaceutical executive with more than 35 years of experience. He is a seasoned builder who possesses vast global commercial and pharmaceutical expertise and a proven ability to build, grow and manage large complex organizations. Before becoming Viatris’ CEO, Smith was President and Chief Operating Officer of Celgene Corp. Most recently, he served as President of BioAtla, Inc., a global biotechnology company focused on the development of Conditionally Active BiologicsTM (CAB) antibody therapeutics. Smith is a member of Viatris board of directors.
Rajiv Malik began his pharmaceuticals career as a scientist and went on to become a leading pharmaceutical industry executive with more than 60 process patents to his name. His deep commercial, scientific and operational experience is an invaluable asset in his role as president of Viatris.
Sanjeev Narula was appointed as the chief financial officer of Viatris following 16 years of experience in senior financial leadership positions at Pfizer. He has a deep understanding of financial and commercial dynamics across geographies and in all Viatris markets.